Breast Neoplasms Clinical Trials in Grand Junction, Colorado

4 studies are recruiting for breast neoplasms in Grand Junction, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

   Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction, Colorado

   Locations

   325 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06966700 on ClinicalTrials.gov

2. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

   The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction, Colorado

   Locations

   360 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07174336 on ClinicalTrials.gov

3. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Intermountain Health, Grand Junction, Colorado

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

4. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

   Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021), Grand Junction, Colorado

   Locations

   199 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07060807 on ClinicalTrials.gov